Document Detail


Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.
MedLine Citation:
PMID:  12196648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The authors have recently described that intrathecal IgM synthesis (ITMS) correlates with a higher disability in patients with clinically definite MS (CDMS). OBJECTIVE: To follow-up a group of patients with MS in the initial stages of the disease to evaluate if the presence of ITMS correlates with a worse evolution. METHODS: Oligoclonal IgM bands were performed in 22 patients with MS with a mean of 1.14 months of evolution. Patients were followed for a period ranging from 6 to 36 months (mean, 21.4 months). During follow-up, time to conversion to CDMS, number of relapses, and changes in Expanded Disability Status Scale (EDSS) score were evaluated. RESULTS: Patients were divided into two groups according to the presence (Group 1, 10 patients) or absence (Group 2, 12 patients) of ITMS. No clinical differences were observed between the groups at inclusion in the study. During the follow-up, the probability of conversion to CDMS was greater in Group 1 (90% of the patients had converted to CDMS after 8 months of follow-up) than in Group 2 (51% of patients had converted to CDMS after 36 months of follow-up) (p = 0.0001). Patients from Group 1 had more relapses (mean, 2.0) than those from Group 2 (mean, 0.58) (p = 0.02). At the end of the study, patients from Group 1 had higher EDSS scores (mean, 1.70) than those from Group 2 (mean, 0.79) (p = 0.02). CONCLUSION: The presence of oligoclonal IgM bands in CSF can be a prognostic marker in the early phases of MS.
Authors:
L M Villar; J Masjuan; P González-Porqué; J Plaza; M C Sádaba; E Roldán; A Bootello; J C Alvarez-Cermeño
Related Documents :
3060548 - Primary drug resistance to both rifampicin and dapsone in a paucibacillary leprosy pati...
22498378 - Late vs early ostomy closure for necrotizing enterocolitis: analysis of adhesion format...
22434468 - Review of kinemax total knee replacements performed at the nhs treatment centre, weston...
17545538 - Multicenter clinical trial of bortezomib in relapsed/refractory waldenstrom's macroglob...
8430368 - Recent advances in the management of fournier's gangrene: preliminary observations.
12380448 - Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. results ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurology     Volume:  59     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-08-28     Completed Date:  2002-09-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  555-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Immunology Hospital Ramón y Cajal, Madrid, Spain. lvillar@hrc.insalud.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Disability Evaluation
Disease Progression
Female
Follow-Up Studies
Humans
Immunoglobulin M / cerebrospinal fluid*
Interferon-beta / therapeutic use
Male
Middle Aged
Multiple Sclerosis / cerebrospinal fluid*,  drug therapy,  immunology*
Predictive Value of Tests
Recurrence / prevention & control
Severity of Illness Index
Chemical
Reg. No./Substance:
0/Immunoglobulin M; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region.
Next Document:  Transcranial magnetic stimulation for the treatment of seizures: a controlled study.